Tirzepatide nigitabo gishya GIP / GLP-1 reseptor agonist yerekanye amasezerano akomeye mukuvura indwara ziterwa na metabolike. Mu kwigana ibikorwa bya hormone ebyiri karemano ya incretine, byongera imisemburo ya insuline, bigabanya urugero rwa glucagon, kandi bikagabanya gufata ibiryo - bifasha cyane kugenzura glucose yamaraso no guteza imbere ibiro.
Ku bijyanye n’ibimenyetso byemewe, tirzepatide kuri ubu yemerewe gucunga glucose yamaraso ku barwayi barwaye diyabete yo mu bwoko bwa 2 ndetse no gucunga ibiro birebire ku bantu bafite umubyibuho ukabije cyangwa umubyibuho ukabije. Ivuriro ryayo rishyigikirwa cyane nubushakashatsi bwinshi: urukurikirane rwikigereranyo rwa SURPASS rwerekanye ko tirzepatide igabanya cyane urwego rwa HbA1c kurwego rwinshi kandi ikarusha ubuvuzi buriho nka semaglutide. Mu micungire y’ibiro, ibizamini bya SURMOUNT byatanze ibisubizo bitangaje - abarwayi bamwe bagabanutseho ibiro 20% mu gihe cyumwaka umwe, bashyira tirzepatide nkimwe mu miti igabanya ubukana ku isoko.
Kurenga diyabete n'umubyibuho ukabije, ibishobora gukoreshwa na tirzepatide biraguka. Ibigeragezo bikomeje kuvurwa birimo gushakisha uburyo byakoreshwa mu kuvura indwara nka steatohepatite itari inzoga (NASH), indwara zimpyiko zidakira, no kunanirwa k'umutima. Ikigaragara ni uko mu cyiciro cya 3 SUMMIT igeragezwa, tirzepatide yerekanye igabanuka rikabije ryibintu biterwa no kunanirwa k'umutima mu barwayi bafite ikibazo cyo kunanirwa k'umutima hamwe n'uduce duto twabitswe (HFpEF) n'umubyibuho ukabije, bitanga ibyiringiro bishya ku buryo bwagutse bwo kuvura.
Igihe cyo kohereza: Nyakanga-24-2025